Trial Profile

A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab or Other Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; SQZ PBMC HPV (Primary) ; Ipilimumab; Nivolumab
Indications Anal cancer; Cervical cancer; Head and neck cancer; Penile cancer; Rectal cancer; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors SQZ Biotech

03 Nov 2023 According to SQZ media release, data from this study presented at the Society for Immunotherapy of Cancer Annual Meeting 2023.
03 Nov 2023 Results presented in a SQZ Biotech Media Release.
25 Jul 2023 According to a SQZ Biotech media release, initial data from this study are anticipated in the second half of 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com